MiNA Therapeutics to Present Initial Results from First-in-Human MTL-CEBPA Study at the 2018 ASCO Annual Meeting

MiNA Therapeutics to Present Initial Results from First-in-Human MTL-CEBPA Study at the 2018 ASCO Annual Meeting --Data from first clinical saRNA candidate in advanced liver cancer will be highlighted in Poster Discussion Session-- London, United Kingdom, May 16, 2018 – MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced that it will present preliminary results from its Phase I study of small activating RNA (saRNA) candidate MTL-CEBPA in liver cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from June 1 – 5. The data will be featured in a Poster Discussion Session in the Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics session. MiNA will announce the results through a press release following the presentation. Poster Discussion Session details: Title: Preliminary results of a first-in-human, first-in-class phase I study of MTL- CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer Abstract No: 2509 Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Date / Time: June 4, 2018 at 3:00pm – 4:15pm Location: S406 About MTL-CEBPA MTL-CEBPA consists of a double stranded RNA formulated into a SMARTICLES® liposomal nanoparticle and is designed to activate the CEBPA gene. By restoring CEBPA expression to normal levels, MTL-CEBPA has been demonstrated to attenuate or reverse liver disease in a range of pre-clinical studies including models of liver cancer, liver cirrhosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). MTL-CEBPA is currently under evaluation in OUTREACH, a first-in-human Phase I clinical study in patients with severe liver cancer. The multi-centre Phase I study is assessing the safety and tolerability of MTL-CEBPA in patients with advanced liver cancer who are ineligible or resistant to standard therapies. To learn more about the OUTREACH clinical study, please visit our listing at clinicaltrials.gov About MiNA Therapeutics Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. www.minatx.com Contact: MiNA Therapeutics Robert Habib, CEO Phone: +44 208 811 6700 E-Mail: [email protected] Media requests: Gretchen Schweitzer or Joanne Tudorica Trophic Communications Phone: +49 89 2388 7735 or +49 172 861 8540 E-Mail: [email protected]

The release as fetched from its publisher. minatx.com ↗